Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.650
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
1.620
-0.030 (-1.82%)
After-hours: Mar 28, 2025, 7:12 PM EDT
Geron Revenue
In the year 2024, Geron had annual revenue of $76.99M with 32,386.92% growth. Geron had revenue of $47.54M in the quarter ending December 31, 2024, with 206,582.61% growth.
Revenue (ttm)
$76.99M
Revenue Growth
+32,386.92%
P/S Ratio
13.84
Revenue / Employee
$336,218
Employees
229
Market Cap
1.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 76.99M | 76.76M | 32,386.92% |
| Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
| Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
| Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
| Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
GERN News
- 2 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - PRNewsWire
- 8 days ago - Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK) - Accesswire
- 11 days ago - Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Geron Corp: How Concerned Should We Be About Rytelo Sales? - Seeking Alpha
- 13 days ago - GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN - PRNewsWire
- 16 days ago - Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN) - GlobeNewsWire
- 19 days ago - Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS - Business Wire
- 19 days ago - Geron Corporation Announces Departure of Chief Executive Officer - Business Wire